{"id":9326,"date":"2021-04-21T13:22:45","date_gmt":"2021-04-21T20:22:45","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9326"},"modified":"2021-04-22T13:23:30","modified_gmt":"2021-04-22T20:23:30","slug":"a-real-world-evaluation-of-the-safety-and-immunogenicity-of-the-covishield-vaccine-chadox1-ncov-19-corona-virus-vaccine-recombinant-in-health-care-workers-hcw-in-national-capital-region-ncr-of","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/21\/a-real-world-evaluation-of-the-safety-and-immunogenicity-of-the-covishield-vaccine-chadox1-ncov-19-corona-virus-vaccine-recombinant-in-health-care-workers-hcw-in-national-capital-region-ncr-of\/","title":{"rendered":"A Real World Evaluation of the Safety and Immunogenicity of the Covishield Vaccine ChAdOx1 NCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India A Preliminary Report"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> A real-world study of the safety and immunogenicity of one dose of the Covishield (Oxford-AstraZeneca) vaccine among healthcare workers in India (n = 1,638) found that <\/span><span style=\"font-weight: 400\">79.0% were seropositive 2 weeks after the 1st dose, an increase from the 48.2% who were seropositive at baseline. Among those with prior infection, 98.2% were seropositive. No serious adverse events were reported. <\/span><i><span style=\"font-weight: 400\">[Editorial Note: Covishield is the trade name of the Oxford-<\/span><\/i><i><span style=\"font-weight: 400\">Astrazeneca ChadOx1 vaccine AZD1222 that is manufactured in India].<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Kataria et al.\u00a0(Apr 20, 2021). A Real World Evaluation of the Safety and Immunogenicity of the Covishield Vaccine ChAdOx1 NCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India A Preliminary Report. Pre-print downloaded Apr 21 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.14.21255452\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.14.21255452<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] A real-world study of the safety and immunogenicity of one dose of the Covishield (Oxford-AstraZeneca) vaccine among healthcare workers in India (n = 1,638) found that 79.0% were seropositive 2 weeks after the 1st dose, an increase from the 48.2% who were seropositive at baseline. Among those with prior infection, 98.2% were&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/21\/a-real-world-evaluation-of-the-safety-and-immunogenicity-of-the-covishield-vaccine-chadox1-ncov-19-corona-virus-vaccine-recombinant-in-health-care-workers-hcw-in-national-capital-region-ncr-of\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142],"topic":[31],"class_list":["post-9326","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9326"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9326\/revisions"}],"predecessor-version":[{"id":9327,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9326\/revisions\/9327"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9326"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}